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a b s t r a c t
Background: Dyspepsia (including upper abdominal pain, abdominal pain, abdominal discomfort,
epigastric discomfort, and dyspepsia) is a symptom that is carefully monitored during dabigatran
treatment. However, detailed information on dyspepsia, including onset, duration, severity, and use of
drug treatment, has not yet been established in Japanese patients.
Methods: We conducted a multi-center, prospective, open-label, randomized, and parallel-group-
comparison observational study of 309 patients with non-valvular atrial ﬁbrillation who had been
newly prescribed dabigatran at 19 institutes in Japan. Gastrointestinal adverse events were evaluated
using the Global Overall Severity (GOS) scale self-reports to describe symptoms and to assess frequency
and severity of symptoms (Part 1). Thereafter, patients with a GOS score Z3 were randomized to receive
a 4-week course of a proton pump inhibitor, an H2-receptor antagonist or a gastric mucosal protective
drug (Part 2).
Results: The incidence of dyspepsia symptoms due to dabigatran was 17.2% (53/309, 95% conﬁdence
interval 13.1–21.8%), with 77% of events occurring within 10 days of initiation. Five patients discontinued
the study because of dyspepsia. At the end of the observation period, the mean GOS score of those
reporting dyspepsia was 3.571.7, with 11.3% (35/309) reporting a score Z3. Substantial differences in
the incidence of dyspepsia were observed between the study institutes (0–41%). In the multivariate
regression analysis, no signiﬁcant factor was found to affect incidence or severity of dyspepsia. The
majority (83–100%) reported that symptoms improved with treatment (GOS score r2), and there was no
signiﬁcant difference between the three different treatment groups.
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Conclusions: The reported symptoms of dyspepsia were generally mild, but were moderate in approxi-
mately 10% of patients. Proton pump inhibitors, H2-receptor antagonists, and rebamipide seemed to be
equally effective in relieving dabigatran-related dyspepsia (umin-CTR UMIN000007579).
& 2014 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
1. Introduction
Dabigatran etexilate, an orally administered pro-drug, is rapidly
converted by a serum esterase to dabigatran, a potent, direct, and
competitive inhibitor of thrombin. It has an absolute bioavailability of
6.5% and a serum half-life of 12–17 h, with 80% of the administered
dose being excreted by the kidneys. Dabigatran is reported to have low
potential for drug–drug interactions, and no drug–food interactions. It
also has the advantage of not requiring therapeutic monitoring [1].
The therapeutic effects of dabigatran in patients with atrial ﬁbrillation
(AF) have been evaluated in several clinical trials at doses of 220 mg
twice daily and 300 mg daily [2–4].
The Randomized Evaluation of Long-Term Anticoagulation
Therapy (RE-LY) [4] trial was designed to compare two ﬁxed doses
of dabigatran (110 mg or 150 mg twice daily) with open-label use
of warfarin in 18,113 patients from 44 countries who had atrial
ﬁbrillation, and were at increased risk for stroke. The trial
demonstrated that the incidences of stroke and hemorrhage were
lower in patients administered dabigatran than in those adminis-
tered warfarin. However, the only adverse effect (AE) that was
signiﬁcantly more common in dabigatran patients than in warfarin
patients was dyspepsia (deﬁned as upper abdominal pain, abdom-
inal pain, abdominal discomfort, epigastric discomfort, and dys-
pepsia). An analysis of the 326 Japanese participants in the RE-LY
trial found that the efﬁcacy and safety proﬁle of dabigatran were
essentially the same in Japanese participants as the rest of the
study population, but that the incidence of dyspepsia was higher [5].
The RE-COVER double-blind, double-dummy, randomized trial of
6 months of treatment with dabigatran (150 mg twice daily)
compared with dose-adjusted warfarin in 2539 patients with AF
reported a signiﬁcantly higher incidence of dyspepsia in the
dabigatran group (2.9%) versus the warfarin group (0.6%).
However, the deﬁnition of dyspepsia differed from that chosen
by the RE-LY investigators [6]. These large trials suggest that
dyspepsia is a relatively common and important side effect of
dabigatran treatment. However, none used dyspepsia-like symp-
toms as a pre-deﬁned endpoint, nor did they record onset, time
course and duration, symptom description and localization, or
severity of the symptoms.
Joyce et al. [7] reported that patients with AF commonly
reported dyspepsia. Self-reported dyspepsia is more common in
those with more severe AF and a higher comorbidity burden. The
extent of self-reported dyspepsia also correlated with a lower
likelihood of reported administration of appropriate AF pharma-
cotherapy or anticoagulation for stroke prevention.
Consequently, we undertook a prospective observational study
to evaluate and determine the incidence and severity of dyspepsia
in Japanese patients with non-valvular atrial ﬁbrillation (NVAF) at
high risk of stroke who had been newly prescribed dabigatran. In
addition, we evaluated the efﬁcacy and safety of proton pump
inhibitors, H2-receptor antagonists, and gastric mucosal protective
drugs in patients who developed symptoms of severe dyspepsia
(Z3 of on a Global Overall Severity, GOS score [8]) after commen-
cing dabigatran by means of a randomized, open-labeled, parallel-
group comparison study.
2. Material and methods
The study was approved by the institutional review board at
each participating study site. Prior to commencing any study
procedure, the purposes and methods of this study were explained
to all participants. Written informed consent was obtained from
each participant. The study was conducted in accordance with the
principles of the Declaration of Helsinki as well as the ethical
guidelines for clinical studies [9].
2.1. Study design
This observational study was conducted using a multi-center,
prospective, open-label, randomized, and parallel-group compar-
ison design. The outline of the study schedule is shown in Fig. 1.
In the study, a total of 309 patients with NVAF who had been
newly prescribed dabigatran between April 2012 and January 2013
at 19 institutes in Japan were enrolled. Each participant subjec-
tively scored dyspepsia symptoms especially for digestive AEs of
dabigatran using the GOS scale to evaluate frequency, description
and severity (Table 1).
Fig. 1. Study protocol. b.i.d., twice daily; NVAF, non-valvular atrial ﬁbrillation; and GOS, Global overall severity.
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This study consisted of two parts: Part 1 was to investigate the
incidence and severity of dabigatran-related dyspepsia symptoms
targeted all enrolled patients and Part 2 was to evaluate the
therapeutic efﬁcacy and safety of proton pump inhibitors,
H2-receptor antagonists, and gastric mucosal protective drugs
prescribed to subjects who had experienced dyspepsia symptoms
with a GOS score of 3 or higher during Part 1 of the study.
The primary endpoints were the frequency, description, and
severity of dyspepsia symptoms during the observational study
period, and the improvement rates of dyspepsia symptoms when
patients were administered proton pump inhibitors, H2-receptor
antagonists and gastric mucosal protective drugs.
The secondary endpoints of the study were
 Proportion of patients with improvement in the severity of
dyspepsia symptoms by 2 points or more on the GOS scale.
 Proportion of patients with resolution of dyspepsia symptoms
(where the resolution was deﬁned as a reduction in GOS
score to 1).
 Proportion of patients with improvement in dyspepsia symp-
toms (where improvement was deﬁned as those patients who
still had dyspepsia symptoms but the GOS score was reduced to
1 or 2).
 Post-treatment severity of dyspepsia symptoms compared with
baseline (i.e., change in the GOS score from baseline).
 Safety, measured by the occurrence of stroke, systemic embo-
lism, bleeding, and discontinuation of dabigatran administra-
tion because of any adverse events (AEs).
2.2. Study subjects
Male and female patients who were in- or out-patients at the
study hospitals who met all of the following criteria were eligible
to be enrolled in Part 1 of the study: (1) a diagnosis of NVAF
(paroxysmal, persistent, or permanent); (2) dabigatran therapy
was to be initiated to prevent ischemic stroke and systemic
embolism associated with NVAF; (3) had no symptoms of dyspep-
sia at baseline (dyspepsia, upper abdominal pain, abdominal pain,
abdominal discomfort, or epigastric discomfort); (4) aged 20 years
or older at the time of giving consent; and (5) capable of providing
written consent in person to participate in the study. For Part 2,
participants in Part 1 who had met all the following criteria were
eligible to proceed to Part 2 of the study: (1) administered
dabigatran for prevention of ischemic stroke and systemic embo-
lism associated with NVAF; and (2) had experienced symptoms of
dyspepsia with a GOS score of 3 or higher during Part 1.
The key exclusion criteria were: (1) undergoing dialysis or diag-
nosis of a severe renal disorder (creatinine clearance o30mL/min):
(2) on-going hemorrhage; (3) diagnosis of any organic lesion
posing a clinically signiﬁcant risk for bleeding (including onset of
hemorrhagic stroke within the past 6 months); (4) having a spinal
or epidural catheter in situ; and (5) use of oral itraconazole.
Participants in Part 1 who met any of the following exclusion
criteria were not eligible to proceed to Part 2: (1) use of proton
pump inhibitors, H2-receptor antagonists or rebamipide during
Part 1; (2) occurrence of dyspepsia symptoms not attributable to
dabigatran, such as excess alcohol consumption, overeating, acute
stress or being administered concomitant medication with other
drugs known to cause dyspepsia; (3) diagnosis of upper gastro-
intestinal bleeding or peptic ulcer disease during Part 1; and
(4) diagnosis of gastroesophageal reﬂux disease conﬁrmed by
endoscopy or radiograph during Part 1.
Eligible participants were prescribed oral dabigatran with
150 mg (75 mg capsule2) administered twice daily or 110 mg
(110 mg capsule1) administered twice daily based on the dosage
regimen approved in Japan. The daily dose of dabigatran was
selected by the investigators, and was based on patients' renal
function, age, and risk of bleeding. In cases when dabigatran
replaced warfarin, dabigatran was initiated when the international
normalized ratio (INR) was o2.0.
The incidence and severity of dyspepsia symptoms were
evaluated for 4 weeks, or until the GOS score for the severity of
dyspepsia exceeded 2. At the end of the observation period (week 4),
patients whose GOS score remained 2 or less were excluded the
study. Patients eligible for the second registration were rando-
mized to one of three treatment groups: a proton pump inhibitor
group, a H2-receptor antagonist group or a mucosal protective
agent group. A dynamic allocation method was applied with
adjustment factors for age (o70 years, Z70 years), gender, and
severity of dyspepsia symptoms (GOS score 3, 4, or Z5).
Based on the treatment group randomized at the second
registration, one drug from the treatment group listed below
was administered for 4 weeks; generic products were acceptable.
At the time of entry into the second registration, patients already
taking a mucosal protective agent or other products to treat gastric
ulcer or gastritis (including over-the-counter drugs) were asked to
discontinue treatment to avoid concomitant administration.
Acceptable drugs were
(1) Proton pump inhibitors: omeprazole, lansoprazole, rabepra-
zole, or esomeprazole.
(2) H2-receptor antagonists: famotidine, ranitidine, nizatidine,
lafutidine, cimetidine, or roxatidine.
(3) Mucosal protective agent: rebamipide.
2.3. Data analysis
The frequencies and summary statistics of demographic data
were calculated for eligible patients at primary registration in
patients with and without dyspepsia. The incidence and 95%
conﬁdence intervals (CIs), days to reporting of symptoms
(mean7standard deviation [SD]), and severity of symptoms
(GOS score: mean7SD) at the end of Part 1 were calculated.
Adverse events and adverse drug reactions (ADRs) due to dabiga-
tran were summarized by events. Factors that might have affected
the incidence and severity of dyspepsia symptoms were subject to
exploratory evaluation.
In Part 2 of the study, we analyzed the frequencies and
summary statistics of demographic data of each treatment group
to verify their homogeneity, the rate of improvement in symptoms
of each group deﬁned by the proportion achieving GOS severity
scores of 1 or 2, and the occurrence of AEs and ADRs attributable
to dabigatran summarized by the events and treatment group.
We estimated that a total of 500 patients were needed to
establish the frequency and severity of dyspepsia symptoms
Table 1
Symptom severity in the global overall symptom (GOS) scale [8].
1. No problem
2. Minimal problem (can be easily ignored without effort)
3. Mild problem (can be ignored with effort)
4. Moderate problem (cannot be ignored but does not
inﬂuence my daily activities)
5. Moderately severe problem (cannot be ignored and occasionally
limits my daily activities)
6. Severe problem (cannot be ignored and often limits my concentration
on daily activities)
7. Very severe problem (cannot be ignored and markedly limits my daily
activities and often requires rest)
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during administration of dabigatran. Based on the sub-group
analysis of 326 Japanese patients in the RE-LY trial [5], the
incidence of dyspepsia was approximately 25%. We estimated that
the number of subjects for second registration was a total of 120
patients (40 patients for each group). We supposed that this target
number of patients to perform an exploratory evaluation of the
effects of treatment on dyspepsia symptoms in treated groups.
Data analysis was conducted by Mebix Co. Ltd. (Tokyo, Japan)
using the SAS program (ver. 9.3).
3. Results
This study was conducted from April 2012 to January 2013 at 19
institutes in Japan. We enrolled 309 patients with NVAF who had
been newly prescribed dabigatran. The disposition of study
patients is summarized in Fig. 2.
3.1. Part 1 of the study
3.1.1. Characteristics of study patients
Patients' characteristics at enrollment are summarized in
Table 2. The mean age of the patients was 66.5 years, and 62.8%
were female. Approximately 38% had a history of warfarin treat-
ment. The mean CHADS2 score was 1.3 [10].
3.1.2. Dosage and adherence to dabigatran
A daily dose of 220 mg (110 mg capsule2, b.i.d.) was the most
common dabigatran dosage (264/309, 85.4%) followed by 300 mg
(150 mg capsule2, b.i.d; 41, 13.3%) and 150 mg (75 mg
capsule2, b.i.d; 4, 1.3%). The patient adherence to dabigatran
was good; 278 (91.7%) patients administered 100% of the dosage
and 21 (6.9%) administered Z75% but no patient failed to take any
dabigatran (1 administered Z50%, and less than 75% and 3 for
o50%).
The total interruption rate of dabigatran treatment was 6.5%
(20/309), and the breakdown in treatment was due to bleeding
ADRs in 1.3% (gastrointestinal bleeding: 1 case, hematuria: 2 cases,
ulorrhagia: 1 case, epistaxis: 1 case), other ADRs in 1.0% (skeletal
muscle pain: 1 case, drug eruption: 1 case, and intolerance: 1 case),
dyspepsia symptoms 1.6% (5 cases), development of complications
0.3% (intravitreal suspended solids: 1 case), and other reasons 2.3%
(7 cases).
3.1.3. Incidence, days to reporting, and severity of dyspepsia
symptoms
Incidences, days to expression, and severities of dyspepsia
symptoms are summarized in Table 3.
In the total study patients (n¼309), the incidence of dyspepsia
symptoms was 17.2% (53/309, 95% CI: 13.1–21.8%), mean days to
reporting of dyspepsia symptoms was 7.1 days (min.: 1 day, max.:
22 days, and median: 5 days), and the mean severity of symptoms
(GOS score) at the end of Part 1 was 3.571.7 (min.: 1.0, max.: 7.0,
and median: 4.0). Nearly 80% (41/53) of the events occurred
within 10 days after initiation of dabigatran treatment. A total of
11.3% (35/309, 95% CI: 8.0–15.4%) of patients had a GOS score Z3
at the end of Part 1 of the study. Dyspepsia was most common
(7.4%), followed by epigastric discomfort (5.5%), and abdominal
discomfort (4.9%). Upper abdominal pain showed the shortest days
to occurrence (min.: 2 days, max.: 15 days, and mean: 4.8 days)
and abdominal discomfort showed the longest days to occurrence
(min.: 1 day, max.: 22 days and mean: 9.5 days).
In patients who were administered continuous drug treatment
for gastritis and gastric ulcer (n¼50), the incidence of dyspepsia
symptoms was 18.0% (95% CI: 8.6–31.4%), mean days to reporting
of symptoms was 11.4 days (min.: 6 days, max.: 22 days, and
median: 9 days), and mean severity of dyspepsia symptoms (GOS
score) at the end of Part 1 was 4.2 (min.: 1.0, max.: 7.0, and
median: 4.0). A comparison of each symptom showed abdominal
discomfort had the highest incidence (10.0%, 5/50) following by
dyspepsia (4.0%, 2/50) and epigastric discomfort (4.0%, 2/50),
which were comparable ﬁgures to those for total patients.
3.1.4. Differences in incidence of dyspepsia symptoms among study
institutes
The incidence of dyspepsia symptoms by study institute are
summarized in Fig. 3. The highest incidence (41%) was shown in
institute G followed by institute H (38%) and institute I (33%),
while 6 institutes reported no incidence of dyspepsia symptoms.
Fig. 2. Study participant ﬂow chart. IC, informed consent.
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3.1.5. Developments of stroke, systemic embolism, and bleeding
events
To evaluate the safety of dabigatran, key events including
stroke, systemic embolism, and bleeding were investigated. No
stroke or systemic embolismwas reported during the Part 1 period
of the study. However, bleeding events occurred in six patients
(1.9%), including one case of gastrointestinal bleeding (severe,
interrupted), three cases of epistaxis (mild to moderate, inter-
rupted), two cases of hematuria (mild to moderate, discontinued),
and one case of ulorrhagia (mild to moderate, interrupted). The
outcome for all of these patients was that they all recovered or
symptoms improved.
3.1.6. Odds ratios per patients' background factors on dyspepsia
To investigate the inﬂuence of patient baseline characteristics
on the incidence or severity of dyspepsia symptoms, odds ratios
and their 95% CIs were calculated for each of nine baseline
characteristics, and the results are summarized in forest plots
(Fig. 4).
Multivariate stepwise regression analysis found that none of
the nine recorded patient characteristics (age, sex, body mass
index (BMI), creatinine clearance, use of concomitant antiplatelet
agents, previous use of warfarin, history of peptic ulcers, previous
use of drugs for gastric ulcer or gastritis, or daily dose of
dabigatran) was signiﬁcantly associated with the incidence or
severity of dyspepsia symptoms (Fig. 4).
Table 2
Participant baseline characteristics at enrollment.
Item (n¼309) Item (n¼309)
Age (years) 66.579.5a Diabetes mellitus 46 (14.9%)
Z70 years 128 (41.4%)b Hypertension 207 (67.0%)
Gender (Female) 194 (62.8%) Hyperlipidemia 109 (35.3%)
BMI 24.073.6 Ccr (mL/min) 80.2727.0
Atrial ﬁbrillation Ccr o30 0 (0.0%)
Paroxysmal 174 (56.9%) Ccr r50 24 (7.8%)
Persistent 60 (19.6%) Ccr 450 285 (92.2%)
Permanent 72 (23.5%) History of warfarin use 118 (38.2%)
CHADS2 score 1.371.1 Use of drugs for gastric ulcer or gastritis 50 (16.2%)
History of gastroduodenal ulcer 18 (5.8%) Proton pump inhibitors 27 (8.7%)
History of cerebrovascular disease 29 (9.4%) H2-receptor antagonists 11 (3.6%)
History of coronary artery disease 22 (7.1%) Rebamipide 12 (3.9%)
History of congestive heart failure 43 (13.9%)
Abbreviations: BMI, body mass index; CHADS2, a clinical prediction tool for estimating the risk of stroke in patients with non-rheumatic atrial ﬁbrillation [10]; and Ccr:
creatinine clearance.
a Mean7standard deviation.
b Number of patients (percentage).
Table 3
Incidence, days to reporting, and severities of dyspepsia symptoms.
Frequencya (patients) Incidence (%, 95% CI) Days to reporting GOS score at the end of Part 1
(a) Total study patients (n¼309)
No. of patients with dyspepsia symptoms 53 17.2 [13.1–21.8] 7.175.6b 3.571.7
Dyspepsia 23 7.4 [4.8–11.0] 6.374.1 3.371.4
Upper abdominal pain 5 1.6 [0.5–3.7] 4.875.7 4.072.6
Abdominal pain 1 0.3 [0.0–1.8] 4.0 6.0
Abdominal discomfort 15 4.9 [2.7–7.9] 9.576.8 3.371.6
Epigastric discomfort 17 5.5 [3.2–8.7] 7.175.8 3.871.6
(b) Patients on continuous drug treatment for gastritis and gastric ulcer (n¼50)
No. of patients with dyspepsia symptoms 9 18.0 [8.6–31.4] 11.475.4b 4.272.2
Dyspepsia 2 4.0 [0.5–13.7] 8.0 4.070.0
Upper abdominal pain 1 2.0 [0.1–10.6] 15.0 2.0
Abdominal pain 0 – – –
Abdominal discomfort 5 10.0 [3.3–21.8] 11.577.1 3.872.3
Epigastric discomfort 2 4.0 [0.5–13.7] 11.0 6.570.7
Abbreviations: GOS, global overall severity; 95% CI, 95% conﬁdence intervals.
a including patients in whom “Days to reporting” could not be identiﬁed.
b Mean7SD.
Fig. 3. Part 1: Incidences of dyspepsia symptoms by study institute (n¼309).
Proportion (%) of patients with dyspepsia symptoms in enrolled study patients.
Two institutes were excluded as no participants were enrolled in the study.
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3.2. Part 2 of the study: therapeutic effect of peptic ulcer treatments
on dyspepsia
In Part 2 of the study, we evaluated any improvement from
administering drugs for gastric ulcer or gastritis in patients with
severity of dyspepsia symptoms of GOS scores Z3 at the end of
Part 1 (Fig. 5). Out of 35 patients with dyspepsia of Z3 of GOS
score, 11 patients discontinued the study, and 2 patients could not
be randomized according to the attending physician's decision. As
a result, because the number of the enrolled patients was smaller
than expected, we suggest that these results should be considered
to be exploratory.
Dyspepsia symptoms improved within 4 weeks in all treatment
groups (Fig. 5): the mean extent of improvement in GOS score
from baseline in each group was similar (proton pump inhibitor
group improved from 4.0 to 1.6, H2-receptor antagonist group
from 4.1 to 1.7 and rebamipide group from 4.3 to 1.8). Almost all
patients (83–100%) improved, i.e. GOS scores changed to r2 at
Week 4 (end of Part 2) from Z3 at baseline (end of Part 1). No
stroke, systemic embolism, or bleeding event was reported during
the Part 2 period of the study.
4. Discussion
We evaluated and determined the incidence and severity of
subjective reports of dyspepsia symptoms due to dabigatran.
Based on the results of the RE-LY trial [4], the AE that was
signiﬁcantly more common with dabigatran than with warfarin
was dyspepsia. In the sub-group (326 Japanese patients) analysis
of the RE-LY trial [5], the incidence of dyspepsia symptoms in
Japanese patients increased to approximately 25%. Therefore,
based on this information regarding dyspepsia, care for gastro-
intestinal symptoms should be required to use dabigatran for
stroke prevention in daily clinical practice in Japan.
Sobieraj et al. [11] reported on the mechanisms that might be
responsible for GI symptoms attributable to antithrombotic agents
used for stroke prevention in AF. Aspirin directly irritates the
gastric mucosa and impairs the ability of prostaglandins to provide
mucosal protection [12]. Dabigatran is formulated in pellets con-
taining a tartaric acid core as a low pH is required to enhance
absorption, which may lead to higher rates of dyspepsia and the
increased risk of GI bleeding with the 150 mg dose [4]. Generally,
drug-induced esophageal or upper GI ulcers develop because of
contact of drugs with the upper GI mucosa and their subsequent
retention there [13]. The mechanism of injury resulting from
bisphosphonates includes destruction of the phospholipid layer [14].
Okada et al. [15] found exfoliative esophagitis or esophageal ulcers in
the middle-lower esophagus with white membraniform attachments
in the endoscopic examination of patients with AF who complained of
symptoms suggestive of GI irritation. This ﬁnding supports a role for
dabigatran's galenic formulation, and, therefore, the incidence of
dyspepsia does not differ with differing doses of dabigatran.
The observed incidence of dyspepsia symptoms was 17.2% (95%
CI: 13.1–21.8%) and this incidence was considerably lower than the
approximately 25% reported in the sub-group analysis of Japanese
patients in the RE-LY study. Nonetheless, in the original analysis of
the RE-LY study, dyspepsia occurred in 707 patients (11.8%) and
688 patients (11.3%) in the 110-mg and 150-mg dabigatran groups,
respectively (Po0.001 for both comparisons), and these incidences
were lower than our result of 17.2%. Therefore, the incidence of
dyspepsia symptoms due to dabigatran may vary from 10% to 20%.
Fig. 4. Part 1: Odds ratios of the impact of patients' background factors on dyspepsia symptoms and its variables (n¼309). In a Forest plot, the closed dot (●) indicates the
odds ratio, and horizontal bar represents the 95% conﬁdence intervals (95% CI). A vertical line at 1 indicates that there is no difference between categories. If the 95% CI does
not cross or touch the vertical line at 1, it means that there is a statistically signiﬁcant difference between the categories (α¼0.05). BMI, body mass index and Ccr: creatinine
clearance.
Fig. 5. Part 2: inﬂuence of pharmacologic treatment on dyspepsia symptoms. nOne
patient in the rebamipide group dropped out having withdrawn informed consent.
GOS, Global overall severity.
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We were not able to identify any risk factors for the develop-
ment of dyspepsia symptoms from the nine characteristics that we
recorded. Although there were trends to suggest that sex, BMI, and
previous use of warfarin might be inﬂuential, these did not reach
statistical signiﬁcance. We were surprised that a history of upper
gastrointestinal ulcer proved not to be a signiﬁcant risk factor for
dyspepsia. The reasons are unclear, but our ﬁnding may be
explained by differences in the mechanisms of mucosal injury
caused by non-steroidal anti-inﬂammatory drugs and dabigatran.
There were very large differences in the incidences of dyspep-
sia symptoms reported from our study institutes, which ranged
from 0% to 41%. This could be explained by the observation that
most institutes that reported no incidence only enrolled a smaller
number of patients (r15 patients), or that explanations or
guidance about potential adverse reactions given to patients
initiated on dabigatran may have differed between investigators.
In Part 2 of the study, the number of patients with GOS scores
Z3 at the end of Part 1 (7 or 8 patients for each treatment group)
was considerably lower than preliminary planned estimation
(40 patients for each treatment group). Consequently, the number of
patients in Part 2 was too small to evaluate and compare the
improvement effects among drugs for gastric ulcer or gastritis on
dabigatran-related dyspepsia, other than that each class of drug
appeared to be effective within 4 weeks of starting treatment.
These ﬁndings might indicate that the mechanisms underlying
dyspepsia are totally different between other gastrointestinal-
toxic drugs and dabigatran.
In general, dabigatran was well tolerated by patients in this
observational study. Dyspepsia occurred in 17.2% of patients at
initiation of therapy, but was mild or moderate in intensity. When
dyspepsia symptoms were more intrusive in patients, it responded
well to treatment with proton pump inhibitors, H2-receptor
antagonists, or rebamipide.
5. Conclusions
This prospective observational study was conducted to evaluate
the incidence and degree of severity of subjectively reported
patient symptoms of dyspepsia due to dabigatran treatment. The
incidence of dyspepsia symptoms (GOS scale 4¼3) was 17.2%. We
found no signiﬁcant factors in patient characteristics that could
predict dyspepsia symptoms, although the incidence was signiﬁ-
cantly different among the different study institutes that partici-
pated in the study. Proton pump inhibitors, H2-receptor
antagonists, and rebamipide improved the dyspepsia symptoms
due to dabigatran treatment.
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